CarthroniX
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
43364 10th St W Ste A, Lancaster, Califo...Phone Number
(949) 885-1907Website
www.carthronix.comRevenue
<$5 MillionIndustry
About CarthroniX
CarthroniX is harnessing the regenerative power of a pathway classically associated with inflammation and pathology: gp130 and the IL-6 family of cytokines. By selectively biasing signaling outcomes from gp130, CarthroniX's small molecules empower unique results in pathological situations. CX-011, CarthroniX's first gp130 modulator, will begin human testing in a Phase 1/2a trial in 2023. Evaluation of other gp130 modulators in veterinary medicine as well as other human indications is actively ongoing.Explore more
CarthroniX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to CarthroniX
Compare insights from companies similar to CarthroniX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CarthroniX
<$5M
1-10
Private
<$5M
2015
AN
Amir NobakhtCommercialization Chief Operating Officer & Director
CarthroniX Tech Stack
A closer look at the technologies used by CarthroniX
See more technologies
Top Business Services Companies
Frequently Asked Questions Regarding CarthroniX
Sign Up For FreeTo access detailed company insights
CarthroniX is harnessing the regenerative power of a pathway classically associated with inflammation and pathology: gp130 and the IL-6 family of cytokines. By selectively biasing signaling outcomes from gp130, CarthroniX's small molecules empower unique results in pathological situations. CX-011, CarthroniX's first gp130 modulator, will begin huma... Read More
